Premium
Research Roundtable Considers Novel Treatment Approaches for Alzheimer's Disease
Author(s) -
Weninger Stacie,
Sperling Bjorn,
Bain Lisa J.,
Carillo Maria C.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.09.082
Subject(s) - library science , citation , medicine , gerontology , psychology , computer science
Although recent clinical trials of treatments for Alzheimer’s disease (AD) have been disappointing, research advances give scientists reasons to be optimistic, said Stacie Weninger, PhD, president of F-Prime Biomedical Research Initiative (FBRI), who along with Lundbeck’s Bjorn Sperling, MD, co-chaired the spring 2019 Alzheimer’s Association Research Roundtable (AARR) meeting on active immunotherapy and alternative therapeutic methods. “The revolution in technologies is enabling us to think about treating diseases in ways that were not possible even five years ago,” said Weninger. AARR brought together experts from academia, industry, and governmental agencies to explore how these new technologies might enable AD treatment breakthroughs as well as help overcome the challenges and risks associated with their implementation. Much of the innovation discussed at the meeting has been driven by the revolution in genomics, through which more than 45 genes or loci have been linked to the risk of developing AD [1]. Genetic studies have focused attention on three key pathways associated with increased risk: processing of amyloid-beta (Ab) and tau, neuroimmune interactions, and lipid metabolism [2]. Multiple innovative methods for potential treatment of AD have emerged from this improved mechanistic understanding of AD, including active immunotherapy, antisense oligonucleotide (ASO) therapies, RNA interference (RNAi), gene therapy and gene editing, targeted protein degradation, and stem cell-based therapies.